UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
(Check One): ☐
Form 10-K ☐ Form 20-F ☐
Form 11-K ☒ Form 10-Q ☐
Form 10-D ☐ Form N-CEN ☐
Form N-CSR
For Period Ended: September 30, 2026
| ☐ |
Transition Report on Form 10-K |
| ☐ |
Transition Report on Form 20-F |
| ☐ |
Transition Report on Form 11-K |
| ☐ |
Transition Report on Form 10-Q |
For the Transition Period Ended: _____________________________________
|
Read Instructions (on back page) Before Preparing
Form. Please Print or Type.
Nothing in this form shall be construed to imply
that the Commission has verified any information contained herein. |
If the notification relates to a portion of the
filing checked above, identify the Item(s) to which the notification relates:
PART I – REGISTRANT INFORMATION
China Pharma Holdings, Inc.
Full Name of Registrant:
N/A
Former Name if Applicable:
Second Floor, No. 17, Jinpan Road
Address of Principal Executive Office (Street and number):
Haikou, Hainan Province, China 570216
City, State and Zip Code
PART II – RULES 12b-25(b) AND (c)
If the subject report could not be filed without
unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed (Check box
if appropriate)
| |
(a) |
|
The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; |
| |
|
|
|
| ☒ |
(b) |
|
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and |
| |
|
|
|
| |
(c) |
|
The accountant’s statement or other exhibit required by Rule 12(b)-25(c) has been attached if applicable. |
PART III – NARRATIVE
State below in reasonable detail why Forms
10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time
period.
The compilation, dissemination and review of the
information required to be presented in the quarterly report on Form 10-Q for the quarterly period ended September 30, 2026 (the “Quarterly
Report”) imposed time constraints that have rendered timely filing of the Quarterly Report impracticable without undue hardship
and expense to the registrant. In accordance with Rule 12b-25 of the Securities Exchange Act of 1934, as amended, the registrant endeavors
to file its Quarterly Report no later than November 23, 2026.
PART IV – OTHER INFORMATION
(1) Name and telephone number of person to contact
in regard to this notification:
| Zhilin Li |
|
+86-898 |
|
6681-1730 |
| (Name) |
|
(Area Code) |
|
(Telephone Number) |
(2) Have all other periodic reports required under
Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12
months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
☒
Yes ☐ No
(3) Is it anticipated that any significant change
in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included
in the subject report or portion thereof?
☒
Yes ☐ No
If so, attach an explanation of the anticipated
change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be
made.
Management estimates to have several material
changes to the registrant’s results of operations, which are still subject to change upon the completion of the financial statements,
including: (i) revenue increased to approximately $1.15 million for the three months ended September 30, 2026 from approximately $0.76
million for the three months ended September 30, 2025; (ii) loss from operations increased to approximately $1.88 million for the three
months ended September 30, 2026 from approximately $0.63 million for the three months ended September 30, 2025; (iii) net loss increased
to approximately $1.90 million for the three months ended September 30, 2026 from approximately $0.65 million for the three months ended
September 30, 2025; and (iv) comprehensive loss increased to approximately $1.49 million for the three months ended September 30, 2026
from approximately $0.59 million for the three months ended September 30, 2025. Additional narrative and quantitative disclosure regarding
the registrant’s results of operations for the three months ended September 30, 2026 will be disclosed in the registrant’s
Quarterly Report on Form 10-Q.
| |
China Pharma Holdings, Inc. |
|
| |
(Name of Registrant as Specified in Charter) |
|
has caused this notification to be signed on its
behalf by the undersigned hereunto duly authorized.
| Date: November 17, 2026 |
By: |
/s/ Zhilin Li |
| |
|
Name: Zhilin Li |
| |
|
Title: Chief Executive Officer
(Principal Executive Officer) |
|
ATTENTION
Intentional misstatements or omissions of fact
constitute Federal criminal violations. (See 18 U.S.C. 1001). |